CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia

J. Levine, I. Goldberger, A. Rapaport, M. Schwartz, C. Schield, A. Elizur, R. H. Belmaker, J. Shapiro, G. Agam

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Inositol is a key metabolite in the phosphatidylinositol cycle, which is a second messenger system for serotonin-2 receptors that have been implicated in the pathophysiology of schizophrenia. Cerebrospinal fluid inositol levels were measured in 20 schizophrenic patients and 19 age- and sex-matched controls and no difference was found. However, the patients were all neuroleptic-treated. A controlled double-blind crossover trial of 12 g daily of inositol for a month in 12 anergic schizophrenic patients, twice the dose given before in schizophrenia, did not show any beneficial effects. However, the number of patients studied was small and the length of time of inositol administration may not have been sufficient.

Original languageEnglish
Pages (from-to)487-490
Number of pages4
JournalEuropean Neuropsychopharmacology
Issue number4
StatePublished - 1 Jan 1994
Externally publishedYes


  • Cerebrospinal fluid
  • Depression
  • Inositol
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)


Dive into the research topics of 'CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia'. Together they form a unique fingerprint.

Cite this